Details for Patent: 7,320,999
Summary for Patent: 7,320,999
| Title: | Dimethyl fumarate for the treatment of multiple sclerosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Rajendra Kumar Joshi, Hans-Peter Strebel | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Biogen International GmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US10/197,077 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,320,999 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 7,320,999 covered the use of dimethyl fumarate as the sole multiple-sclerosis treatment active ingredient, including oral capsules, solid dosage forms, enteric-coated microtablets, and specified 50 mg, 110 mg, and 120 mg quantities. The patent expired on June 9, 2020, eliminating its current blocking effect in the United States. Its commercial importance was tied to Biogen's Tecfidera, an FDA-approved delayed-release dimethyl fumarate product. US Patent 7,320,999: Scope, Claims, Expiration, Litigation, and Tecfidera Patent LandscapeWhat does US Patent 7,320,999 protect?US 7,320,999 protects a method of treating multiple sclerosis by administering a pharmaceutical preparation in which dimethyl fumarate is the only active ingredient directed to treating multiple sclerosis. The patent does not claim dimethyl fumarate as a compound. It claims a therapeutic use and specific pharmaceutical presentations. The patent is therefore a method-of-treatment patent with dependent claims directed to dosage amounts, capsules, oral administration, solid dosage forms, microtablets, enteric coatings, particle size, carriers, and excipients.
The patent family originated from European and international filings relating to the use of fumaric acid esters, including dimethyl fumarate, in multiple sclerosis. The US patent term ran 20 years from the relevant nonprovisional filing date, subject to any applicable patent-term adjustment. The FDA Orange Book identified the patent as a Tecfidera patent. [1, 2] What does independent claim 1 require?Claim 1 has four material limitations:
The claim does not specify:
A product or treatment could therefore fall within claim 1 without using the formulation details recited in claims 2 through 18, provided the preparation uses dimethyl fumarate as the sole multiple-sclerosis treatment active ingredient and is administered for MS treatment. The phrase "only active ingredient for the treatment of multiple sclerosis" is narrower than a requirement that dimethyl fumarate be the only pharmacologically active substance in the entire product. The claim language permits carriers, excipients, and potentially other active ingredients directed to unrelated conditions, subject to the facts of a particular product and the applicable claim construction. How do claims 2 through 18 narrow the patent scope?The dependent claims create several overlapping protection categories.
Claim 16 is the most commercially specific claim. It requires a capsule containing 120 mg of dimethyl fumarate in enteric-coated microtablets with a mean diameter from 0.3 mm to 2.0 mm, measured without the coating. The patent does not require the precise Tecfidera label, brand name, capsule color, release profile, or a particular excipient package. A competing product could avoid claim 16 by changing one or more limitations, such as the dose, dosage form, microtablet size, or use of an enteric coating. Before expiration, such design-around strategies would have had to be evaluated against the broader claim 1 and the intermediate claims. Does US 7,320,999 cover Tecfidera?Yes. Tecfidera is an oral delayed-release dimethyl fumarate product approved by the FDA for relapsing forms of multiple sclerosis. The initial FDA approval covered 120 mg and 240 mg delayed-release capsules. The 120 mg capsule presentation corresponded closely to claim 16's recitation of 120 mg of dimethyl fumarate in enteric-coated microtablets. [3] The patent's claims were broader than the marketed product in some respects:
Tecfidera's 240 mg maintenance dose also fell within claim 2's 10 to 300 mg range and claim 4's "at least 50 mg" limitation. The 120 mg starter dose was expressly recited in claims 6, 8, 9, and 16. When did US 7,320,999 lose exclusivity?The patent expired on June 9, 2020. After that date, the patent could no longer block an ANDA applicant or commercial launch based on the US patent right. The key US exclusivity timeline was:
FDA regulatory exclusivity and patent exclusivity were separate. The five-year NCE period prevented submission or approval of certain ANDAs during the statutory period, while the patent restricted conduct covered by the patent claims. [3, 4] What was the Paragraph IV litigation involving US 7,320,999?Biogen sued Mylan after Mylan filed an ANDA seeking approval of generic delayed-release dimethyl fumarate capsules. The litigation was brought in the US District Court for the District of Delaware as Biogen International GmbH v. Mylan Pharmaceuticals Inc. Mylan's Paragraph IV position challenged the patent's validity and enforceability and asserted that its proposed product would not infringe the patent. The central validity issue was obviousness. The district court found the asserted claims invalid for obviousness. Biogen appealed. The US Court of Appeals for the Federal Circuit later reversed the district court's obviousness determination, holding that the trial court had not established the required motivation to combine the prior art with a reasonable expectation of success. The Federal Circuit decision preserved the patent's validity during the appellate dispute, although the patent had already reached its June 9, 2020 expiration date by the time generic entry became commercially relevant. [5, 6] The litigation had several practical consequences:
What prior art created validity risk for the patent?The principal technical validity issue concerned whether the use of dimethyl fumarate for multiple sclerosis was obvious in view of earlier fumarate disclosures. Relevant prior-art themes included:
The patent's commercial success did not by itself resolve validity. The litigation focused on whether a skilled person would have selected dimethyl fumarate for MS treatment and expected it to work based on the prior art. The Federal Circuit placed weight on the absence of a sufficient showing that the skilled person would have had a reasonable expectation of success. [5] The patent's strength was uneven across claim categories:
What other patents covered Tecfidera?US 7,320,999 was the foundational use patent, but Biogen's broader Tecfidera patent strategy included later patents directed to formulations, delayed release, dosage forms, and related pharmaceutical compositions. Representative later Orange Book-listed patent families included:
The exact Orange Book status of each patent depended on the reference-listed drug, patent listing, statutory disclaimer, term adjustment, and litigation history. Later patents were more important to generic-entry analysis after the expiration of US 7,320,999 because they could target the commercial product's delayed-release formulation rather than the underlying MS use alone. [2] What is the Orange Book status of US 7,320,999?The FDA Orange Book listed US 7,320,999 for Tecfidera during the period when the patent was in force. Its listing identified patent protection associated with the drug product and was relevant to ANDA certifications. After expiration, the patent ceased to provide a live US patent barrier. An Orange Book listing does not extend patent term. It also does not independently establish infringement. The listing connects the patent to the approved drug for regulatory certification purposes. [2] The patent should therefore be treated as:
Which companies challenged or entered the dimethyl fumarate market?Mylan was the most prominent early challenger in the litigation involving US 7,320,999. Other generic manufacturers pursued or obtained approval for dimethyl fumarate delayed-release capsules after the relevant patent and exclusivity barriers declined. The competitive set included generic manufacturers such as:
Generic entry depended on more than the expiration of US 7,320,999. Applicants also had to address:
Is there biosimilar risk for Tecfidera?No. Tecfidera is a small-molecule drug, not a biologic. It is subject to the ANDA generic pathway rather than the biosimilar pathway under the Public Health Service Act. The relevant competitive threat is generic dimethyl fumarate, not a biosimilar. FDA approval depends primarily on pharmaceutical equivalence and bioequivalence to the reference product, including the delayed-release dosage form. What formulation and manufacturing barriers remain after patent expiry?The expired patent's enteric-coated microtablet claims described one formulation architecture, but manufacturing complexity can still affect generic competition. Important technical barriers include:
These are regulatory and manufacturing barriers, not substitutes for an expired patent. A manufacturer can face development and approval costs even when no enforceable patent blocks entry. Later formulation patents may also create risk if the generic product copies protected features of the reference product. How strong was the commercial value of US 7,320,999?The patent was commercially important because it covered the therapeutic use underlying Tecfidera, a major MS product. Biogen reported Tecfidera revenue of approximately $4.4 billion in 2019, before generic competition materially affected the product's commercial position. [7] Its commercial strength came from the combination of:
Its economic weakness was the fixed patent expiration date. Once the patent expired, the broad claim no longer protected the market from generic products, even though later formulation patents could continue to affect entry strategy. What generic launch scenarios existed after expiration?Three entry scenarios were commercially relevant:
Because US 7,320,999 expired in 2020, its own claim scope no longer determines current launch timing. Current analysis must focus on remaining Orange Book patents, settlement terms, FDA approval status, and product-specific infringement exposure. Did Biogen settle with generic challengers?The public record around Tecfidera included patent litigation, generic challenges, and commercial-entry negotiations. Settlement analysis must be performed challenger by challenger because agreements can differ in launch date, licensing rights, authorized-generic provisions, and treatment of later patents. US 7,320,999 itself cannot support a current settlement-based launch restriction after expiration. Any continuing settlement impact would have to arise from other patents, contractual terms, or separate regulatory arrangements. Key Takeaways
FAQsCan a generic company practice claim 1 after June 9, 2020?Yes. The patent expiration removes the US patent restriction created by claim 1, subject to other valid patents and regulatory requirements. Does US 7,320,999 cover fumaric acid esters other than dimethyl fumarate?The asserted claims provided here specifically require dimethyl fumarate. They do not, on their face, cover other fumaric acid esters. Does the patent require treatment with exactly 120 mg?No. Claim 1 has no dose limitation. Claims 2 and 4 through 9 introduce dose limitations, and claim 16 specifically recites 120 mg. Could a tablet avoid the patent's capsule claims?A tablet could avoid claims requiring a capsule, including claim 3 and claim 16. It could still implicate claim 1, claim 2, claim 4, claim 7, claim 8, claim 9, claim 10, claim 11, or other claims depending on its dose and use. Is a product with another active ingredient automatically outside claim 1?No. Claim 1 excludes another active ingredient for treating multiple sclerosis. It does not necessarily exclude every other pharmacologically active substance directed to an unrelated condition. References
More… ↓ |
Drugs Protected by US Patent 7,320,999
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,320,999
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 198 53 487 | Nov 19, 1998 |
International Family Members for US Patent 7,320,999
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1131065 | ⤷ Start Trial | C300675 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1131065 | ⤷ Start Trial | CA 2014 00036 | Denmark | ⤷ Start Trial |
| European Patent Office | 1131065 | ⤷ Start Trial | PA2014023 | Lithuania | ⤷ Start Trial |
| European Patent Office | 1131065 | ⤷ Start Trial | 92488 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1131065 | ⤷ Start Trial | 39/2014 | Austria | ⤷ Start Trial |
| European Patent Office | 1131065 | ⤷ Start Trial | 1490039-3 | Sweden | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
